Abstract
Disclosed is a method and a brexanolone containing oral composition for treating CNS disorders such as depression. An embodiment of the invention comprises orally administering a brexanolone containing composition to a subject having a CNS disorder. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability and a predetermined ratio of bioavailability in a fed state administration relative to a fasted state administration.
Full Text
What is claimed is:
Disclosed is a method and a brexanolone containing oral composition for treating CNS disorders such as depression. An embodiment of the invention comprises orally administering a brexanolone containing composition to a subject having a CNS disorder. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability and a predetermined ratio of bioavailability in a fed state administration relative to a fasted state administration.
Timeline
Filed
03/12/2026Published
07/16/2026Granted
Not AvailableIPC Codes(3)
A61K 31/57:substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 9/20:Pills, lozenges or tablets
A61K 9/48:Preparations in capsules, e.g. of gelatin, of chocolate